Tags

Type your tag names separated by a space and hit enter

The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?
Neurourol Urodyn. 2017 02; 36(2):390-393.NU

Abstract

AIMS

The main objective of this study was to define urinary biomarkers that can predict the severity of overactive bladder and detect patients who would benefit most from treatment.

METHODS

Patients with an OAB diagnosis and healthy controls were included in the study. A bladder diary and a validated OAB questionnaire were given to all patients. In the OAB group, solifenacin 5 mg daily was given for 1 month. Urine samples were taken before the treatment and after the first month of the treatment in both groups and urinary BDNF, NGF, GAG, and MCP-1 levels were measured.

RESULTS

A total of 45 OAB patients and 45 healthy age-matched controls were included. BDNF/Cre, NGF/Cre, MCP-1/Cre, and GAG/Cre levels were significantly higher in the OAB group. The levels of these biomarkers significantly decreased after 1 month of solifenacin treatment. After treatment, 66.7% of patients OAB symptoms were relieved and 33.3% did not respond to the treatment. Although basal biomarker levels did not differ between responder and non-responder groups, the ratio of decrease in biomarker levels was significantly higher in treatment-sensitive patients. Postmenopausal women were more resistant to treatment when compared with the premenopausal group.

CONCLUSIONS

Urinary biomarkers have a role in the pathophysiology of OAB however they did not predict the patients who would benefit from the treatment and in whom antimuscarinics would be useless. Future studies with higher numbers of patients and different OAB subgroups are needed to investigate the exact role of these (and other) biomarkers. Neurourol. Urodynam. 36:390-393, 2017. © 2015 Wiley Periodicals, Inc.

Authors+Show Affiliations

Department of Urology, Pamukkale University School of Medicine, Denizli, Turkey.Department of Urology, Pamukkale University School of Medicine, Denizli, Turkey.Department of Urology, Pamukkale University School of Medicine, Denizli, Turkey.Department of Biochemistry, Pamukkale University School of Medicine, Denizli, Turkey.Department of Urology, Pamukkale University School of Medicine, Denizli, Turkey.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26661444

Citation

Alkis, Okan, et al. "The Use of Biomarkers in the Diagnosis and Treatment of Overactive Bladder: Can We Predict the Patients Who Will Be Resistant to Treatment?" Neurourology and Urodynamics, vol. 36, no. 2, 2017, pp. 390-393.
Alkis O, Zumrutbas AE, Toktas C, et al. The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment? Neurourol Urodyn. 2017;36(2):390-393.
Alkis, O., Zumrutbas, A. E., Toktas, C., Aybek, H., & Aybek, Z. (2017). The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment? Neurourology and Urodynamics, 36(2), 390-393. https://doi.org/10.1002/nau.22939
Alkis O, et al. The Use of Biomarkers in the Diagnosis and Treatment of Overactive Bladder: Can We Predict the Patients Who Will Be Resistant to Treatment. Neurourol Urodyn. 2017;36(2):390-393. PubMed PMID: 26661444.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment? AU - Alkis,Okan, AU - Zumrutbas,Ali Ersin, AU - Toktas,Cihan, AU - Aybek,Hulya, AU - Aybek,Zafer, Y1 - 2015/12/10/ PY - 2015/08/17/received PY - 2015/11/18/accepted PY - 2015/12/15/pubmed PY - 2017/12/27/medline PY - 2015/12/15/entrez KW - biomarkers KW - brain derived neurotrophic factor KW - glycosaminoglycans KW - monocyte chemoattractant protein 1 KW - nerve growth factor KW - overactive bladder SP - 390 EP - 393 JF - Neurourology and urodynamics JO - Neurourol Urodyn VL - 36 IS - 2 N2 - AIMS: The main objective of this study was to define urinary biomarkers that can predict the severity of overactive bladder and detect patients who would benefit most from treatment. METHODS: Patients with an OAB diagnosis and healthy controls were included in the study. A bladder diary and a validated OAB questionnaire were given to all patients. In the OAB group, solifenacin 5 mg daily was given for 1 month. Urine samples were taken before the treatment and after the first month of the treatment in both groups and urinary BDNF, NGF, GAG, and MCP-1 levels were measured. RESULTS: A total of 45 OAB patients and 45 healthy age-matched controls were included. BDNF/Cre, NGF/Cre, MCP-1/Cre, and GAG/Cre levels were significantly higher in the OAB group. The levels of these biomarkers significantly decreased after 1 month of solifenacin treatment. After treatment, 66.7% of patients OAB symptoms were relieved and 33.3% did not respond to the treatment. Although basal biomarker levels did not differ between responder and non-responder groups, the ratio of decrease in biomarker levels was significantly higher in treatment-sensitive patients. Postmenopausal women were more resistant to treatment when compared with the premenopausal group. CONCLUSIONS: Urinary biomarkers have a role in the pathophysiology of OAB however they did not predict the patients who would benefit from the treatment and in whom antimuscarinics would be useless. Future studies with higher numbers of patients and different OAB subgroups are needed to investigate the exact role of these (and other) biomarkers. Neurourol. Urodynam. 36:390-393, 2017. © 2015 Wiley Periodicals, Inc. SN - 1520-6777 UR - https://www.unboundmedicine.com/medline/citation/26661444/The_use_of_biomarkers_in_the_diagnosis_and_treatment_of_overactive_bladder:_Can_we_predict_the_patients_who_will_be_resistant_to_treatment L2 - https://doi.org/10.1002/nau.22939 DB - PRIME DP - Unbound Medicine ER -